2024 Agenda


*All times are in MST


Fri 13

2:00PM -3:00PM

Meeting registration

3:00PM -3:10PM

Meeting objectives & introduction
Naval Daver

3:10PM -4:35PM

Session 1: Updates on established therapies in AML – Part 1
Chairs: Andrew Wei & Eytan Stein

  • IC+VEN in newly diagnosed fit AML – current status and patient selection: Tapan Kadia
  • Deciphering the biological basis of the GVL effect: Paresh Vyas
  • Optimizing transplant outcomes in AML and role of maintenance post ASCT: Charles Craddock
  • Role and optimal maintenance strategies in AML patients not going to ASCT: Maximilian Stahl
  • CPX updates & new data: Tara Lin

Panel Discussion

4:35PM -6:00PM

Session 2: Translational and lab developments and applications in AML
Chairs: Ravi Majeti & Paresh Vyas

  • Antigen targets and novel CAR-T strategies: Ravi Majeti
  • Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy: Koichi Takahashi
  • Potential for early intervention in CHIP and CCUS: Uma Borate
  • Designing and applying a FLT3 like signature in AML: Adrián Mosquera Orgueira
  • Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld

Panel discussion

6:30PM -8:00PM

Welcome reception


Sat 14

8:10AM -9:20AM

Session 3: Updates on established therapies in AML – Part 2
Chairs: Naval Daver & Charles Craddock

  • Optimal approach to treatment of secondary/therapy related AML: Jorge Cortes
  • IDHm impacts treatment of younger adults with AML: Courtney DiNardo
  • Frontline approaches for FLT3-mutant AML: Naval Daver
  • Current approaches and challenges for relapsed FLT3-mutant AML: Alexander Perl

Panel discussion

9:20AM -10:50AM

Session 4: International trials group
Chairs: Courtney DiNardo & Paresh Vyas

  • HOVON: Paresh Vyas
  • MDACC: Naval Daver
  • UK trials: Charles Craddock
  • Australian trials: Andrew Wei
  • French trials: Stéphane de Botton
  • myeloMATCH: Richard Little

Panel discussion

10:50AM -11:10AM


11:10AM -12:15PM

Session 5: IC vs HMA+VEN for all non-FLT3 mutated patients >60 years of age regardless of physical fitness
Chairs: Mark Levis and Jessica Altman

Pro: Eunice Wang and Tapan Kadia – in favour of HMA+ VEN

Con: Harry Erba and Stéphane de Botton – in favour of IC

12:15PM -1:15PM


1:15PM -2:10PM

Session 6: New frontiers in MRD for AML clinical practice
Chairs: Stéphane de Botton & Gail Roboz

  • Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
  • MRD as a clinical endpoint in clinical trials: Nicholas Short
  • Applying MRD techniques in FLT3-mutated AML – are we able to use MRD as an endpoint?: Christopher Hourigan

Panel discussion

2:10PM -3:20PM

Session 7: BPDCN & MDS/MPN + CMML
Chairs: Marina Konopleva & Mrinal Patnaik

  • Updates in diagnosis, pathogenesis, and future directions in BPDCN: Marina Konopleva
  • VEXAS syndrome: Emma Groarke
  • Future targets and drug development in CMML: Mrinal Patnaik
  • AP/BP MPN to post-MPN AML: Anand Patel

Panel discussion

3:20PM -3:40PM


3:40PM -4:50PM

Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & Roland Walter

  • Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT: Yngvar Fløisand
  • Which patients with AML in MRD+ remission should be transplanted?: Roland Walter
  • Early phase CAR-T and NK cell trials for R/R AML and MDS: Nelli Bejanyan
  • NK cell-based therapies in AML: Jeffrey Miller

Panel discussion

4:50PM -5:50PM

Session 9: Special session on regulatory endpoints in AML
Chairs:  Naval Daver & Courtney DiNardo

  • The FDA’s perspective on regulatory endpoints in AML: Kelly Norsworthy
  • A clinical investigator’s perspective on drug development and endpoints: Gail Roboz

Panel discussion

Day 1 wrap-up

Faculty Dinner


Sun 15

9:00AM -9:05AM

Introduction to Day 3

9:05AM -9:55AM

Session 10: Menin inhibition
Chairs: Naval Daver & Jessica Altman                                                                                              

  • Single-agent menin inhibitors – efficacy, biomarkers and resistance: Eunice Wang
  • Updates on menin inhibitor-based combination in AML: Ghayas Issa
  • Frontline triplets with menin inhibitors in AML: Joshua Zeidner
    Panel discussion
9:55AM -10:50AM

Session 11: Novel targets, combinations and treatments in AML Part 1 – new AML therapies and limitations
Chairs: Richard Stone & Marina Konopleva

  • Overcoming resistance to venetoclax-based therapies in AML: Marina Konopleva
  • Uproleselan in frontline and R/R AML: Daniel DeAngelo
  • Promising combination options in AZA/VEN for R/R AML: Thomas Cluzeau
    Panel discussion
10:50AM -11:10AM


11:10AM -12:05PM

Session 12: Novel targets, combinations and treatments in AML Part 2
Chairs: Tapan Kadia & Eunice Wang

  • TP53 treatment strategies in AML – how do we crack this nut?: David Sallman
  • Tuspetinib for relapsed or refractory AML: Gabriel Mannis
  • How best to use Plerixafor for our AML patients?: Geoffrey Uy

Panel discussion

12:05PM -1:00PM

Session 13: Novel targets, combinations and treatments in AML Part 3
Chairs: Farhad Ravandi & Catherine Smith

  • Optimal use of OGM and RNA-translocation panel in frontline AML: Sanam Loghavi
  • Novel ADCs in AML – how best to incorporate and use them: Farhad Ravandi
  • Leveraging STING for therapeutic benefit in AML: Andrew Wei


Meeting concludes, followed by lunch